Inhalation Wednesday, April 25, 2018
Skip Navigation LinksHome) Item Details
Inhalation is the only technical publication devoted exclusively to readers involved in development and production of pulmonary or nasal delivered pharmaceuticals.
Technical Articles
Item Details:
Publication Date: 02/2008
Pages: 5
PDF Format
Recommended Item:
Excipients in DPI Formulations

Understanding how lactose and other excipients can affect formulation performance.

Because most conventional dry powder inhaler (DPI) products contain an extremely small dose of active pharmaceutical ingredient (API) in the form of a very fine, highly cohesive powder, the majority of DPIs rely on excipients, especially lactose, to overcome formulation performance problems. Although a few DPIs, such as AstraZeneca’s Turbohaler Pulmicort budesonide product, include no excipients at all, the majority of dry powder formulations contain inhalation grade lactose. The selection of specific characteristics of the lactose used, as well as the use of ternary excipients, can have a significant impact on handling, dose reproducibility, and respiratory deposition efficiency.

To read this entire article:

You may purchase this article now for personal use. Simply click the Buy Item button above, enter your payment details, and download the article. It will be available to you for 7 days for viewing, printing, or saving for future reference. All articles are copyrighted by CSC Publishing, Inc. and cannot be used for commercial purposes without express permission in writing from the Publisher. This includes but is not limited to: web posting, printing, or sharing via email.


Your payment information is forwarded in an encrypted form, using 40- or 128-bit Secure Socket Layer technology, only to our payment gateway ( for processing.


To view an article, you must have Acrobat Reader installed on your computer. Click on the icon to download Acrobat Reader free of charge.

      Copyright 2018, CSC Publishing Inc. ALL Rights Reserved * Privacy policy